Long-term safety and efficacy of tezacaftor/Ivacaftor in patients with cystic fibrosis homozygous for F508del-CFTR or heterozygous for F508del and a residual function mutation: First interim analysis results of a phase 3, open-label, rollover study

The requested reference [d6c92e029ceebed1e0edf83205562f3a10e3d056] no longer exists in our database. It has been replaced by the current reference: [400eac5c139c64b9acdf26c3aae47f2728a97be6]

Authors
Category Primary study
JournalAmerican Journal of Respiratory and Critical Care Medicine
Year 2018
This article has no abstract
Epistemonikos ID: 1959400e52aa23ffa0b3656ce735c21f65f1b4ed
First added on: Feb 09, 2025